Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.62 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.62 |
| ▸ | CCR1 | P32246 | 4/20 | 0.58 |
| ▸ | CCR8 | P51685 | 4/20 | 0.58 |
| ▸ | CCR5 | P51681 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18434624 | 0.82 | CCR1 (0.51) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL7548538 | 0.80 | KDM4E (0.52) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL874272 | 0.80 | PSMD14 (0.67) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL2471617 | 0.78 | SLC40A1 (0.47) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL3803953 | 0.77 | PSMD14 (0.50) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL20176002 | 0.77 | KMT2A (0.49) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL2696188 | 0.77 | PSMD14 (0.62) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL3713624 | 0.77 | PSMD14 (0.62) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL1611156 | 0.77 | NR4A2 (0.53) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL5536434 | 0.77 | PSMD14 (0.62) | PSMD14COPS5CCR1CCR8CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| EP-4291555-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2022173727-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-08-18 | — | — | WO | disclosed |
| US-11396501-B2 | Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-03-17 | — | — | US | disclosed |
| EP-3687540-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CGeneTech (Suzhou, China) Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| WO-2020132459-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2196466-A1 | Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions | NOSCIRA, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-6939969-B2 | Tri-and bidentate amido ligands prepared by palladium0 coupling and metallation thereof to form metal-amido catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-09-06 | — | — | US | disclosed |
| US-20030032808-A1 | Tri-and bidentate amido ligands prepared by palladium0 coupling and metallation threreof to form metal-amido catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-02-13 | — | — | US | disclosed |
| WO-2002079207-A2 | TRI-AND BIDENTATE AMIDO LIGANDS PREPARED BY PALLADIUM0 COUPLING AND METALLATION THEREOF TO FORM METAL-AMIDO CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-5075488-A | Fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-12-24 | — | — | US | disclosed |
| EP-0128006-B1 | A SOIL-DISEASE-CONTROLLING AGENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-4709052-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-11-24 | — | — | US | disclosed |
| EP-0128006-A2 | A soil-disease-controlling agent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-12-12 | — | — | EP | disclosed |
| US-4209419-A | Certain sulfonamidoquinolines, metal complexes thereof, and solutions containing such sulfonamidoquinolines and metal complexes | HENKEL CORPORATION (US) | 1980-06-24 | — | — | US | disclosed |
| US-4100163-A | Substituted 8-sulfonamidoquinolines | GENERAL MILLS CHEMICALS, INC. (US) | 1978-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396501-B2 | Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same | CXCR4, CXCL12, CXCR1 | PSMD14 4783/4885COPS5 3151/4885CCR1 14/4885 |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | HMGB3, HCCS, ACACA | PSMD14 3179/4885COPS5 2774/4885CCR1 477/4885 |
| US-20030032808-A1 | Tri-and bidentate amido ligands prepared by palladium0 coupling and metallation threreof to form metal-amido catalysts | PUF60, PDCD10, HDAC10 | PSMD14 3960/4885COPS5 3254/4885CCR1 4461/4885 |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CXCR4, CXCL12, CXCR1 | PSMD14 4783/4885COPS5 3151/4885CCR1 14/4885 |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | PSMD14 2730/4885COPS5 2122/4885CCR1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.